{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:52:42Z","timestamp":1772761962017,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,1,6]],"date-time":"2016-01-06T00:00:00Z","timestamp":1452038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Quantitative cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) nucleic acid testing (<jats:styled-content style=\"fixed-case\">NAT<\/jats:styled-content>) has been standardized using the World Health Organization (<jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>) international calibration standard. A new <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>\u2010approved <jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>\u2010calibrated assay (<jats:styled-content style=\"fixed-case\">CA<\/jats:styled-content>) was found to be more sensitive than a laboratory\u2010developed test (<jats:styled-content style=\"fixed-case\">LDT<\/jats:styled-content>). We hypothesized that monitoring therapeutic response using a more sensitive assay may lead to longer antiviral therapy in solid organ and hematopoietic stem cell transplant patients with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection. We reviewed transplant patients with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease retrospectively, and divided them into two groups: those diagnosed and managed based on <jats:styled-content style=\"fixed-case\">LDT<\/jats:styled-content> and those managed using <jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CA<\/jats:styled-content>. Compared to patients monitored by <jats:styled-content style=\"fixed-case\">LDT<\/jats:styled-content>, the time to reach an undetectable viral load was significantly longer in the group monitored by the <jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CA<\/jats:styled-content>. However, a trend toward shorter duration of antiviral treatment was observed (median, 34 vs. 41 d; p = 0.058), with earlier discontinuation of induction antiviral therapy upon reaching undetectable viral load using <jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CA<\/jats:styled-content> (11 vs. 18 d; p = 002). We concluded that despite using a more sensitive <jats:styled-content style=\"fixed-case\">CMV NAT<\/jats:styled-content>, the total duration of antiviral treatment was not significantly prolonged in transplant patients with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection and disease. Relapse rates did not differ between the two groups.<\/jats:p>","DOI":"10.1111\/ctr.12671","type":"journal-article","created":{"date-parts":[[2015,11,21]],"date-time":"2015-11-21T10:38:50Z","timestamp":1448102330000},"page":"154-160","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of cytomegalovirus infection and disease pre\u2010 and post\u2010quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration?"],"prefix":"10.1111","volume":"30","author":[{"given":"M. Veronica","family":"Dioverti","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Department of Medicine Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Lahr","sequence":"additional","affiliation":[{"name":"Biomedical Statistics and Informatics Department of Biostatistics Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymund R.","family":"Razonable","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Department of Medicine Mayo Clinic Rochester MN USA"},{"name":"Department of Health Sciences Research The William J. Von Liebig Center for Transplantation and Clinical Regeneration Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12103"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2013.02.005"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00015-13"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis900"},{"key":"e_1_2_8_7_1","unstructured":"JF Fryer Standardization WECoB 2010 World Health Organization Geneva Switzerland"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.01.014"},{"key":"e_1_2_8_9_1","unstructured":"DiovertiM.Correlation of Cytomegalovirus Viral Load between a Laboratory\u2010Developed Test and a WHO\u2010Calibrated Commercial Assay in Transplant Recipients. IDWeek 2014:IDSA;2014."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.12.4472-4476.2001"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit096"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31823c1cd4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-08"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis993"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24216"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.12671","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.12671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:21:18Z","timestamp":1696339278000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.12671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,6]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/ctr.12671"],"URL":"https:\/\/doi.org\/10.1111\/ctr.12671","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,6]]}}}